Aldeyra Therapeutics (ALDX) Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. SPY
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Aldeyra Therapeutics (ALDX) Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics (ALDX) Prices 10M Share IPO at $12.50/Sh

April 29, 2021 5:44 AM EDT

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aldeyra, are expected to be $125 million. In addition,... More

Aldeyra Therapeutics (ALDX) to Resume Trading at 7:30 a.m.

April 27, 2021 7:16 AM EDT

Aldeyra Therapeutics (NASDAQ: ALDX) to Resume Trading at 7:30 a.m.

... More

Aldeyra Therapeutics (ALDX) Halted for News

April 27, 2021 7:02 AM EDT

Aldeyra Therapeutics (NASDAQ: ALDX) Halted for News

... More